Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...

PRINCETON, N.J., March 03, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62 ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best dividend stocks to buy according to billionaires. Dividend stocks have been ...

Bristol Myers Squibb stock (NYSE: BMY) has gained 7% this year, outperforming the S&P 500 which has declined 1%. BMS’s strong Q4 performance has helped drive its positive momentum. While markets ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $60.18, moving +0.6% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.78%.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of $118 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...